Investor Insight
Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III enrollment progress, full ARCHER data, and CRD-38 clinical initiation – are key value drivers in large and underserved cardiovascular markets.
Company Highlights
- Clinical-stage life sciences company developing therapies for heart disease.
- Late-Stage Pipeline: Lead oral drug candidate, CardiolRx™, in the ongoing Phase III MAVERIC trial for recurrent pericarditis (RP).
- Strong Market Potential: Current US revenue for third-line RP therapy is approximately $500 million, with analyst forecasts’ exceeding $1 billion by 2028.
- Validated Target: Focused on inflammasome activation, implicated in multiple cardiac conditions.
- World-class Collaborations: Long-standing collaborations and partnerships with leading international cardiovascular research centers.
- Near-term Milestones – Advance MAVERIC Phase III enrollment (50% targeted H2 2025, full enrollment H1 2026); present full Phase II ARCHER trial results for acute myocarditis in H2 2025; complete IND-enabling work and initiate Phase I for CRD-38 in heart failure.
Overview
Cardiol Therapeutics Inc. (NASDAQ:CRDL,TSX:CRDL) is a clinical-stage life sciences company focused on the research, development, and commercialization of innovative anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company’s programs target serious, often life-threatening cardiovascular conditions for which there are limited or no approved treatments, including recurrent pericarditis, acute myocarditis, and heart failure.
Cardiol’s therapeutic approach centers on modulating inflammasome pathway activation—a central driver of inflammation and fibrosis in the heart. This is achieved through pharmaceutically manufactured cannabidiol formulations developed under cGMP standards. Cannabidiol has been shown in preclinical and clinical studies to down-regulate inflammatory mediators (e.g., IL-1, IL-6) and preserve cardiac structure and function, offering the potential for disease-modifying, non-immunosuppressive treatment options.
INN Disclaimer: This profile is sponsored by Cardiol Therapeutics ( TSX:CRDL ). This profile provides information which was sourced by the Investing News Network (INN) and approved by Cardiol Therapeutics in order to help investors learn more about the company. Cardiol Therapeutics is a client of INN. The company's campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. In exchange for publishing services rendered by INN on behalf of Cardiol Therapeutics named herein, including the promotion by INN of Cardiol Therapeutics in any content on the INN website, the INN receives from Cardiol Therapeutics annual cash compensation of typically up to two hundred and fifty thousand dollars. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Cardiol Therapeutics and seek advice from a qualified investment advisor.